Axon Enterprise (NASDAQ:AXON) Price Target Lowered to $690.00 at Piper Sandler

Axon Enterprise (NASDAQ:AXON) had its price objective reduced by Piper Sandler from $753.00 to $690.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock.

AXON has been the topic of a number of other reports. Royal Bank Of Canada initiated coverage on Axon Enterprise in a report on Monday, November 17th. They set an “outperform” rating and a $860.00 price target on the stock. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. The Goldman Sachs Group decreased their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Morgan Stanley cut their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 17th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $762.93.

Axon Enterprise Stock Performance

Shares of AXON opened at $520.18 on Wednesday. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The firm’s fifty day simple moving average is $539.22 and its two-hundred day simple moving average is $628.00. Axon Enterprise has a 12 month low of $396.41 and a 12 month high of $885.91. The stock has a market capitalization of $41.05 billion, a P/E ratio of 342.23, a price-to-earnings-growth ratio of 13.33 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.94% and a net margin of 4.48%.The company had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. During the same period in the previous year, the business earned $2.08 EPS. The firm’s revenue was up 38.5% compared to the same quarter last year. As a group, analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 100 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total value of $55,063.00. Following the sale, the director owned 1,316 shares in the company, valued at $724,629.08. This represents a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the transaction, the chief accounting officer directly owned 13,740 shares in the company, valued at approximately $8,244,000. The trade was a 7.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 48,040 shares of company stock valued at $27,249,338 over the last quarter. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NEOS Investment Management LLC increased its position in shares of Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after purchasing an additional 11,482 shares during the last quarter. Vanguard Group Inc. raised its position in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after acquiring an additional 5,953 shares during the last quarter. BIT Capital GmbH grew its position in shares of Axon Enterprise by 75.6% during the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after acquiring an additional 1,522 shares during the period. Finally, Wealthedge Investment Advisors LLC increased its stake in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 775 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and raised medium/long-term targets — Axon reported $796.7–797M in Q4 revenue (≈+39% YoY) and $2.15 adjusted EPS, beat consensus, issued 2026 revenue guidance well above street estimates and introduced $6B 2028 revenue/strong margin targets. This is the headline catalyst for the rally. Axon reports Q4 2025 revenue of $797 million
• Positive Sentiment: AI is driving bookings and product demand — Management emphasized AI features across cameras, license-plate readers and evidence management that are accelerating deployments and bookings, helping convert device customers into higher‑margin software subscribers. Taser Maker Axon Says Its Business Is Being ‘Supercharged by AI.’
• Positive Sentiment: Government spending and enterprise demand tailwinds — Reports cite strong device and software demand from federal and public‑safety customers (including DHS initiatives) that support the company’s growth runway. Axon shares rise as Taser-maker’s profit gets boost from government spending
• Positive Sentiment: Some sell‑side firms maintain buy ratings — Several analysts reiterated bullish views or maintained Buy ratings based on the AI-driven platform and long-term targets, supporting the upside narrative. Axon: AI-Driven Platform Strength and Long-Term Growth Targets Support Buy Rating
• Neutral Sentiment: Earnings call and presentation available — Full Q4 earnings call transcript and slides were posted; useful for digging into bookings, margin cadence and product adoption metrics. Axon Enterprise, Inc. (AXON) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short‑interest data reported but inconclusive — A February short‑interest entry shows zero/NaN values and a 0.0 days ratio, which appears to be a data anomaly and shouldn’t be treated as meaningful without confirmation from exchange filings.
• Negative Sentiment: Analysts trimmed price targets despite the beat — Several firms cut targets after the print (UBS, Barclays, Morgan Stanley, Piper Sandler noted cuts in coverage summaries), which can moderate upside expectations even though many kept overweight/buy ratings. These Analysts Cut Their Forecasts On Axon After Q4 Results

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.